Journal of ethnopharmacology · 2026
Mechanic exploration of Yin Jia tablet against chronic salpingitis via the miR-34a-5p-mediated ceRNA network.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wen Lingmiao, Lou Shunping, Zhang Li, Zhou Hang, Tan Ying, Ai Keyu, Liu Xiaotong, Zhang Lu, Ding Weijun, Huang Yefang
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Yin Jia tablet (YJT), a multiherb prescription in traditional Chinese medicine (TCM), has long been clinically applied for the treatment of chronic salpingitis (CS), a primary etiological factor contributing to female infertility. Despite its extensive clinical utilization, the molecular mechanisms underlying its therapeutic efficacy remain unclear.
AIM: The present study aimed to establish a rat model of CS using YJT as a therapeutic intervention and to systematically elucidate the regulatory mechanisms of YJT against CS, with a specific focus on the structure and function of the oviduct.
MATERIALS AND METHODS: Ultrahigh-performance liquid chromatography-quadrupole-Orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap-HRMS) was employed to identify the absorbed constituents in YJT-medicated serum. Serum concentrations of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), and interleukin-17 (IL-17) were measured, and hematoxylin-eosin staining (HE) and transmission electron microscopy (TEM) were performed to observe the oviduct structure. Whole-transcriptome sequencing was subsequently conducted to profile differentially expressed messenger RNAs (mRNAs), microRNAs (miRNAs), and long noncoding RNAs (lncRNAs). A competing endogenous RNA (ceRNA) network was constructed, and the correlations between the expression of these transcripts and the levels of inflammatory cytokines were analyzed. Quantitative real-time polymerase chain reaction (RT‒qPCR) and Immunohistochemistry (IHC) were employed to validate the expression of key transcripts and proteins.
RESULTS: Analysis of the absorbed constituents revealed that citric acid and adenosine may serve as critical ingredients that mediate the therapeutic effects of YJT. Similarly, YJT treatment reduced the serum levels of TNF-α, IL-6, IL-1β, and IL-17. The results from HE staining and TEM demonstrated that YJT effectively restored the integrity of the oviduct epithelium. Whole-transcriptome sequencing revealed that YJT modulated inflammation-related signaling pathways through a miR-34a-5p-centered ceRNA network and that the expression levels of key transcripts were closely correlated with the concentrations of inflammatory cytokines, supported at the protein level.
CONCLUSIONS: YJT exerts multitarget protective effects against CS by regulating the miR-34a-5p-related ceRNA network, which in turn suppresses inflammatory responses and preserves the normal function of the oviduct. These findings provide molecular evidence for the pharmacological basis of YJT in the treatment of CS and further support its potential as a promising therapeutic agent for this condition.
AIM: The present study aimed to establish a rat model of CS using YJT as a therapeutic intervention and to systematically elucidate the regulatory mechanisms of YJT against CS, with a specific focus on the structure and function of the oviduct.
MATERIALS AND METHODS: Ultrahigh-performance liquid chromatography-quadrupole-Orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap-HRMS) was employed to identify the absorbed constituents in YJT-medicated serum. Serum concentrations of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), and interleukin-17 (IL-17) were measured, and hematoxylin-eosin staining (HE) and transmission electron microscopy (TEM) were performed to observe the oviduct structure. Whole-transcriptome sequencing was subsequently conducted to profile differentially expressed messenger RNAs (mRNAs), microRNAs (miRNAs), and long noncoding RNAs (lncRNAs). A competing endogenous RNA (ceRNA) network was constructed, and the correlations between the expression of these transcripts and the levels of inflammatory cytokines were analyzed. Quantitative real-time polymerase chain reaction (RT‒qPCR) and Immunohistochemistry (IHC) were employed to validate the expression of key transcripts and proteins.
RESULTS: Analysis of the absorbed constituents revealed that citric acid and adenosine may serve as critical ingredients that mediate the therapeutic effects of YJT. Similarly, YJT treatment reduced the serum levels of TNF-α, IL-6, IL-1β, and IL-17. The results from HE staining and TEM demonstrated that YJT effectively restored the integrity of the oviduct epithelium. Whole-transcriptome sequencing revealed that YJT modulated inflammation-related signaling pathways through a miR-34a-5p-centered ceRNA network and that the expression levels of key transcripts were closely correlated with the concentrations of inflammatory cytokines, supported at the protein level.
CONCLUSIONS: YJT exerts multitarget protective effects against CS by regulating the miR-34a-5p-related ceRNA network, which in turn suppresses inflammatory responses and preserves the normal function of the oviduct. These findings provide molecular evidence for the pharmacological basis of YJT in the treatment of CS and further support its potential as a promising therapeutic agent for this condition.